Links WebJust another WordPress weblog

CAMBRIDGE, Mass., June 24 /PRNewswire/ — Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for the Treatment of immune-mediated diseases, announced today that it has been named to the annual FierceBiotech “Fierce 15″ list, designating it as one of the top biotech companies of 2008. The editors of FierceBiotech evaluated hundreds of privately-held firms based on company vision, revenue potential, quality of deals, strength of technology, partnerships, and competitive market position. Tolerx was determined to be one of the “fiercest,” proven by its creativity and innovations in the industry.
An internationally recognized daily newsletter reaching more than 65,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with a quick authoritative briefing on the day’s top stories, with a special focus on drug discovery and clinical trials.
John Carroll, Editor of FierceBiotech, said, “A rich partnership pact with GlaxoSmithKline last October kept Tolerx in the race to develop an anti-CD3 monoclonal antibody for autoimmune disease. That program has now begun a Phase III clinical trial known as DEFEND, and all the chips are on the table.”
“FierceBiotech is renowned for its advanced understanding of biotechnology companies and the industry as a whole,” said Dr. Douglas J. Ringler, President and Chief Executive Officer of Tolerx. “Being selected as a member of the ‘Fierce 15′ is an honor that highlights Tolerx’s potential to make a significant impact in the biotech market.”
The Fierce 15 celebrates the spirit of being “fierce” — championing innovation and creativity, even in the face of intense competition. The complete list of ‘Fierce 15′ companies is available in today’s issue of FierceBiotech and on the FierceBiotech Web site at .
About Tolerx
Tolerx is a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases. Tolerx currently has two antibodies in clinical development for the potential Treatment of various autoimmune indications: otelixizumab, an anti-CD3 MAb which is being developed in collaboration with GlaxoSmithKline and a modified form of TRX1, which is being developed in collaboration with Genentech, Inc. Tolerx is also engaged in preclinical development of new product candidates that circumvent immune system tolerance. These product candidates are being evaluated for the Treatment of cancer or chronic viral diseases. For more information, please visit .
Tolerx Forward-Looking Statements
This press release contains certain statements that include the word “potential”. Such statements, which are not historical facts, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Statements regarding outcomes sought to be realized in the clinical trials or preclinical development, and the potential for Tolerx to make a significant impact in the biotech market are all forward-looking statements. Such forward-looking statements involve risks, uncertainties and other factors that may cause the actual performance or achievements of Tolerx to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. There can be no certainty that Tolerx will advance any clinical candidate or other component of its pipeline to the clinic, to the next regulatory step or to commercialization or that Tolerx will ever realize revenue from commercialization of product candidates it is currently or may in the future seek to develop. Factors and risks that may impact management’s expectations and affect the forward-looking statements include but are not be limited to the sufficiency, scope and breath of the company’s vision, the strength of the company’s technology, the continuation, robustness and resilience of the company’s innovation and creativity, results of DEFEND and other future clinical studies, results of pre-clinical studies, the ability to obtain regulatory approval for advancement of any product candidate, the continuation of the collaborations with GSK and Genentech, the introduction of competing therapies by other companies and changes in the company’s business plan or objectives. These statements reflect the view of Tolerx as of the date of this press release and should not be relied upon as reflecting the company’s views at any date subsequent to this release. Tolerx undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this press release.
Tolerx, Inc.

EDMONTON, May 13 /PRNewswire-FirstCall/ — BioMS Medical Corp (TSX: MS), a leading developer in the Treatment of multiple sclerosis (MS), today announced that Dr. Mark Krantz, Vice President Scientific Affairs, BioMS Medical, will present at the TIDES(R) - Oligonucleotide and Peptide Technology and Product Development Conference in Las Vegas. WHEN: Tuesday May 20th at 10:45 am (PDT) WHERE: Red Rock Casino, Resort and Spa, Las Vegas TITLE: “Late-Stage Clinical Development of Synthetic Peptide MBP8298 for the Treatment of Multiple Sclerosis” About TIDES(R) Conference ————————-TIDES(R) is the only forum that covers manufacturing, formulation, delivery, process and analytical development and overall market trends for peptide- and oligonucleotide-based therapeutics and diagnostics. For more information visit: About BioMS Medical Corp. ————————-BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical’s lead technology, MBP8298, is for the Treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to MBP8298 in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at .This press release may contain forward-looking statements, which reflect the Company’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that MBP8298 will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. BioMS Medical Corp.

XI’AN, China, March 31 /Xinhua-PRNewswire-FirstCall/ — Huifeng Bio- Pharmaceutical Technology, Inc. (BULLETIN BOARD: HFGB) , a developer and producer of plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production, is pleased to announce its audited financial results for the year ended December 31, 2007.Full Year 2007 Highlights:The following is a summary of our financial results for the full year ended Dec. 31, 2007. 12 Months Ended 12 Months Ended Growth In US Dollars December 31,2007 December 31,2006 ACIORFIPROCENTE Net Revenue $6,571,531 $3,076,779 114ACIORFIPROCENTE Gross Profit $1,977,313 $457,518 332ACIORFIPROCENTE Gross Profit Margin 30ACIORFIPROCENTE 15ACIORFIPROCENTE Net Income $1,283,683 $131,736 874ACIORFIPROCENTE Net Income Margin 20ACIORFIPROCENTE 4ACIORFIPROCENTE Earnings Per Share $0.07 $0.01 600ACIORFIPROCENTEHuifeng achieved outstanding growth during 2007, with sales more than doubling and net income increasing by over 800ACIORFIPROCENTE. “Huifeng achieved a number of significant milestones in 2007. We have increased our product offering and achieved significant sales in both Rutin and Diosmin,” states company CEO Jing’An Wang. Furthermore, in late 2007, Huifeng signed the largest supply agreement in company history and completed a $2 million fundraising.”Huifeng expects to continue achieving significant gains in both sales and net income in 2008 through organic growth of our current products,” forecasted Mr. Wang. The company restructured its production lines in the fourth quarter to accommodate the increased production levels of Diosmin necessitated under its current contract with Safic-Alcan of France. Huifeng also hopes to close a strategic acquisition in 2008 under its stated policy of seeking synergistic, accretive acquisitions in the Xi’an region of China.The company is maintaining its stated guidance of sales of US$18 million and net income of US$4 million ($0.18 cents per share) in 2008.For more detailed information on this transaction, investors should refer to Huifeng’s Current Report on Form 10-KSB and related exhibits filed with the Securities and Exchange Commission on Friday, March 31, 2008.This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.About Huifeng Bio-Pharmaceutical Technology, Inc. (HFGB)Huifeng Bio-Pharmaceutical Technology, Inc., located in Xi’an, People’s Republic of China, develops and produces plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production. It is the leading Chinese producer of rutin and related plant-derived chemicals in a class called flavonoids, with medicinal and other beneficial properties. Founded in 2002, Huifeng uses proprietary patented processes to extract rutin more efficiently than traditional extraction techniques. The Company is diversifying its product lines through internal development, acquisition and cooperation with scientific research organizations. This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts, included or incorporated by reference herein relating to management’s current expectations of future financial performance, continued growth, changes in economic conditions or capital markets and our ability to consummate strategic acquisitions are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.Words or phrases such as “anticipates,”"may,”"will,”"should,”"believes,”"estimates,”"expects,”"intends,”"plans,”"hopes,”"predicts,”"projects,”"targets,”"will likely result,”"will continue” or similar expressions identify forward-looking statements. Forward-looking statements involve risks and uncertainties which could cause actual results or outcomes to differ materially from those expressed. We caution that while we make such statements in good faith and believe such statements are based on reasonable assumptions, including without limitation, management’s examination of historical operating trends, data contained in records and other data available from third parties, we cannot assure you that our projections will be achieved. For more information, please contact: Dan Carlson, Primary Capital LLC Email: Huifeng Bio-Pharmaceutical Technology, Inc.